Research
Read how they describe their research on their University of Toronto profile.
Latest papers
Highlight selection of radiochemistry and radiopharmacy developments by editorial board.
EJNMMI radiopharmacy and chemistry · 2024
Vaccinia virus and peptide-receptor radiotherapy synergize to improve treatment of peritoneal carcinomatosis.
Molecular therapy oncolytics · 2023
Highlight selection of radiochemistry and radiopharmacy developments by editorial board.
EJNMMI radiopharmacy and chemistry · 2022
Latest funding
- $852,975
198Au-Nanodepot Combined with Adjuvant Auger Electron Radioimmunotherapy, Immunotherapy and Chemotherapy for Triple-Negative Breast Cancer in Metastatic Humanized Mouse Models
CIHR · 2024 · Nominated PI
- $105,000
Translational studies leading to a clinical trial of PET imaging to evaluate the delivery of 89Zr-labeled pembrolizumab to brain metastases in patients with lung cancer enhanced by MRI-guided focused ultrasound
CIHR · 2023 · Supervisor
- $7,944,656
Rare Isotopes to Transform Cancer Therapy
SSHRC · 2022 · Co-investigator
4 publications.
Highlight selection of radiochemistry and radiopharmacy developments by editorial board.
Toyohara J, Vugts D, Kiss OC, Todde S, Li XG, Liu Z, Yang Z, Gillings N, Cazzola E, Szymanski W, Meulen NV, Reilly R, Taddei C, Schirrmacher R, Li Z, Lagebo YJ, Bentaleb N, Souza Albernaz M, Lapi S, Ramogida C, Mukherjee A, Ajenjo J, Deuther-Conrad W, Bourdeau C
Vaccinia virus and peptide-receptor radiotherapy synergize to improve treatment of peritoneal carcinomatosis.
Ottolino-Perry K, Mealiea D, Sellers C, Acuna SA, Angarita FA, Okamoto L, Scollard D, Ginj M, Reilly R, McCart JA
Highlight selection of radiochemistry and radiopharmacy developments by editorial board.
Toyohara J, Al-Qahtani M, Huang YY, Cazzola E, Todde S, Furumoto S, Mikolajczak R, Decristoforo C, Gillings N, Yang M, Reilly R, Duatti A, Denkova A, Schirrmacher R, Carlucci G, Seimbille Y, Liu Z, Ellis B, Cornelissen BT, Kopka K, Bernardes E
Highlight selection of radiochemistry and radiopharmacy developments by editorial board.
Alves F, Antunes IF, Cazzola E, Cleeren F, Cornelissen B, Denkova A, Engle J, Faivre-Chauvet A, Gillings N, Hendrikx JJMA, Jalilian AR, van der Meulen NP, Mikolajczak R, Neels OC, Pillai MRA, Reilly R, Rubow S, Seimbille Y, Spreckelmeyer S, Szymanski W, Taddei C
198Au-Nanodepot Combined with Adjuvant Auger Electron Radioimmunotherapy, Immunotherapy and Chemotherapy for Triple-Negative Breast Cancer in Metastatic Humanized Mouse Models
Principal investigators: Reilly, Raymond M
Keywords: 111in; 198au; Auger Electrons; Brachytherapy; Epidermal Growth Factor Receptor (Egfr); Humanized Mice; Immunotherapy; Radiation Nanomedicine; Radioimmunotherapy; Triple-Negative Breast Cancer
Translational studies leading to a clinical trial of PET imaging to evaluate the delivery of 89Zr-labeled pembrolizumab to brain metastases in patients with lung cancer enhanced by MRI-guided focused ultrasound
Principal investigators: Borlase, Stephanie
Keywords: Blood-Brain-Barrier (Bbb); Brain Metastases; Lung Cancer; Mri-Guided Focused Ultrasound (Mrig-Fus); Pembrolizumab; Positron Emission Tomography (Pet); Radiopharmaceuticals; Zirconium-89 (89zr)
Rare Isotopes to Transform Cancer Therapy
Principal investigators: Bénard, François
Leveraging Trans-Canada Expertise and Resources to Design and Evaluate Novel Auger Electron-Emitting Radioimmunotherapies (RIT) for Metastatic Triple-Negative Breast Cancer (TNBC)
Principal investigators: Radchenko, Valery; Reilly, Raymond M
Keywords: Radiopharmaceutical Science
Alpha-Particle Radioimmunotherapy of Brain Metastases from HER2-Positive Breast Cancer
Principal investigators: Reilly, Raymond M
Keywords: Actinium-225; Alpha Particles; Auger Electrons; Brain Metastases; Breast Cancer; Focused Ultrasound; Her2; Peptides; Radioimmunotherapy; Trastuzumab
Fundamental Studies of the Effects of Auger Electrons Emitted in Different Subcellular Compartments of Human Cells
Principal investigators: Reilly, Raymond
Keywords: auger electrons; radiobiology; dosimetry; clonogenic survival; subcellular distribution; indium-111; gallium-67; technetium-99m; gold nanoparticles; cancer
A trial to evaluate the safety and feasibility of blood-brain brain opening using MRI-guided focused ultrasound in the treatment of Her2-positive breast cancer brain metastases
Principal investigators: Lipsman, Nir
Keywords: Brain Metastases; Breast Cancer; Focused Ultrasound; Her2; Image-Guided Surgery; Indium-111; Trastuzumab
Auger Electron Radioimmunotherapy for Treatment and Prevention of Metastases from Triple-Negative Breast Cancer
Principal investigators: Reilly, Raymond M
Keywords: Auger Electrons; Breast Cancer; Circulating Tumour Cells; Epidermal Growth Factor Receptors; Metastases; Positron Emission Tomography (Pet); Radioimmunotherapy; Triple-Negative Breast Cancer; Tumour Xenograft Mouse Models
NSERC CREATE in Polymer Nanoparticles for Drug Delivery (POND)
Principal investigators: Moffitt, Matthew MG
Targeted Polymeric Nanotechnology for Multi-Modality Treatment of HER2 Positive Breast Cancer
Principal investigators: Allen, Christine J; Reilly, Raymond M; Sridhar, Srikala S
Keywords: Auger Electron Radiotherapy; Block Copolymer Micelles; Breast Cancer; Docetaxel; Drug Delivery; Her-2; Imaging; Nanotechnology
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Raymond Reilly and Ralf Schirrmacher: 2 shared papers
- Raymond Reilly and Caterina Ramogida: 1 shared paper
- Caterina Ramogida and Ralf Schirrmacher: 1 shared paper
- Pharmaceutical Sciences
- Oncology
- Department of Chemistry
Co-authors at University of Toronto, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.
Profile data last refreshed on September 26, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.